67 related articles for article (PubMed ID: 38532028)
21. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
[TBL] [Abstract][Full Text] [Related]
22. Myxoid glioneuronal tumor, PDGFRA p.K385L-mutant, arising in midbrain tectum with multifocal CSF dissemination.
Kleinschmidt-DeMasters BK; Chiang J; Donson AM; Borges T; Gilani A
Brain Pathol; 2022 Jan; 32(1):e13008. PubMed ID: 34297434
[TBL] [Abstract][Full Text] [Related]
23. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
Jones RL; Serrano C; von Mehren M; George S; Heinrich MC; Kang YK; Schöffski P; Cassier PA; Mir O; Chawla SP; Eskens FALM; Rutkowski P; Tap WD; Zhou T; Roche M; Bauer S
Eur J Cancer; 2021 Mar; 145():132-142. PubMed ID: 33465704
[TBL] [Abstract][Full Text] [Related]
24. PDGF receptor mutations in human diseases.
Guérit E; Arts F; Dachy G; Boulouadnine B; Demoulin JB
Cell Mol Life Sci; 2021 Apr; 78(8):3867-3881. PubMed ID: 33449152
[TBL] [Abstract][Full Text] [Related]
25. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis.
Chen CCL; Deshmukh S; Jessa S; Hadjadj D; Lisi V; Andrade AF; Faury D; Jawhar W; Dali R; Suzuki H; Pathania M; A D; Dubois F; Woodward E; Hébert S; Coutelier M; Karamchandani J; Albrecht S; Brandner S; De Jay N; Gayden T; Bajic A; Harutyunyan AS; Marchione DM; Mikael LG; Juretic N; Zeinieh M; Russo C; Maestro N; Bassenden AV; Hauser P; Virga J; Bognar L; Klekner A; Zapotocky M; Vicha A; Krskova L; Vanova K; Zamecnik J; Sumerauer D; Ekert PG; Ziegler DS; Ellezam B; Filbin MG; Blanchette M; Hansford JR; Khuong-Quang DA; Berghuis AM; Weil AG; Garcia BA; Garzia L; Mack SC; Beroukhim R; Ligon KL; Taylor MD; Bandopadhayay P; Kramm C; Pfister SM; Korshunov A; Sturm D; Jones DTW; Salomoni P; Kleinman CL; Jabado N
Cell; 2020 Dec; 183(6):1617-1633.e22. PubMed ID: 33259802
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment with avapritinib in patient with mucosal metastatic melanoma.
Cocorocchio E; Pala L; Conforti F; Guerini-Rocco E; De Pas T; Ferrucci PF
Ther Adv Med Oncol; 2020; 12():1758835920946158. PubMed ID: 32821296
[TBL] [Abstract][Full Text] [Related]
27. Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features.
Lucas CG; Villanueva-Meyer JE; Whipple N; Oberheim Bush NA; Cooney T; Chang S; McDermott M; Berger M; Cham E; Sun PP; Putnam A; Zhou H; Bollo R; Cheshier S; Poppe MM; Fung KM; Sung S; Glenn C; Fan X; Bannykh S; Hu J; Danielpour M; Li R; Alva E; Johnston J; Van Ziffle J; Onodera C; Devine P; Grenert JP; Lee JC; Pekmezci M; Tihan T; Bollen AW; Perry A; Solomon DA
Brain Pathol; 2020 May; 30(3):479-494. PubMed ID: 31609499
[TBL] [Abstract][Full Text] [Related]
28. Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants.
Pecquet C; Chachoua I; Roy A; Balligand T; Vertenoeil G; Leroy E; Albu RI; Defour JP; Nivarthi H; Hug E; Xu E; Ould-Amer Y; Mouton C; Colau D; Vertommen D; Shwe MM; Marty C; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2019 Jun; 133(25):2669-2681. PubMed ID: 30902807
[TBL] [Abstract][Full Text] [Related]
29. Septal dysembryoplastic neuroepithelial tumor: a comprehensive clinical, imaging, histopathologic, and molecular analysis.
Chiang JCH; Harreld JH; Tanaka R; Li X; Wen J; Zhang C; Boué DR; Rauch TM; Boyd JT; Chen J; Corbo JC; Bouldin TW; Elton SW; Liu LL; Schofield D; Lee SC; Bouffard JP; Georgescu MM; Dossani RH; Aguiar MA; Sances RA; Saad AG; Boop FA; Qaddoumi I; Ellison DW
Neuro Oncol; 2019 Jun; 21(6):800-808. PubMed ID: 30726976
[TBL] [Abstract][Full Text] [Related]
30. Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.
Ip CKM; Ng PKS; Jeong KJ; Shao SH; Ju Z; Leonard PG; Hua X; Vellano CP; Woessner R; Sahni N; Scott KL; Mills GB
Nat Commun; 2018 Nov; 9(1):4583. PubMed ID: 30389923
[TBL] [Abstract][Full Text] [Related]
31. Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile.
Solomon DA; Korshunov A; Sill M; Jones DTW; Kool M; Pfister SM; Fan X; Bannykh S; Hu J; Danielpour M; Li R; Johnston J; Cham E; Cooney T; Sun PP; Oberheim Bush NA; McDermott M; Van Ziffle J; Onodera C; Grenert JP; Bastian BC; Villanueva-Meyer JE; Pekmezci M; Bollen AW; Perry A
Acta Neuropathol; 2018 Aug; 136(2):339-343. PubMed ID: 30006677
[No Abstract] [Full Text] [Related]
32. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.
Bower H; Björkholm M; Dickman PW; Höglund M; Lambert PC; Andersson TM
J Clin Oncol; 2016 Aug; 34(24):2851-7. PubMed ID: 27325849
[TBL] [Abstract][Full Text] [Related]
33. PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.
Arts FA; Chand D; Pecquet C; Velghe AI; Constantinescu S; Hallberg B; Demoulin JB
Oncogene; 2016 Jun; 35(25):3239-48. PubMed ID: 26455322
[TBL] [Abstract][Full Text] [Related]
34. Imatinib mesylate.
Waller CF
Recent Results Cancer Res; 2014; 201():1-25. PubMed ID: 24756783
[TBL] [Abstract][Full Text] [Related]
35. PDGF receptor signaling networks in normal and cancer cells.
Demoulin JB; Essaghir A
Cytokine Growth Factor Rev; 2014 Jun; 25(3):273-83. PubMed ID: 24703957
[TBL] [Abstract][Full Text] [Related]
36. Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.
Paugh BS; Zhu X; Qu C; Endersby R; Diaz AK; Zhang J; Bax DA; Carvalho D; Reis RM; Onar-Thomas A; Broniscer A; Wetmore C; Zhang J; Jones C; Ellison DW; Baker SJ
Cancer Res; 2013 Oct; 73(20):6219-29. PubMed ID: 23970477
[TBL] [Abstract][Full Text] [Related]
37. PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.
Velghe AI; Van Cauwenberghe S; Polyansky AA; Chand D; Montano-Almendras CP; Charni S; Hallberg B; Essaghir A; Demoulin JB
Oncogene; 2014 May; 33(20):2568-76. PubMed ID: 23752188
[TBL] [Abstract][Full Text] [Related]
38. Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.
Alentorn A; Marie Y; Carpentier C; Boisselier B; Giry M; Labussière M; Mokhtari K; Hoang-Xuan K; Sanson M; Delattre JY; Idbaih A
Neuro Oncol; 2012 Nov; 14(11):1393-403. PubMed ID: 23074200
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome.
Pardanani A; D'Souza A; Knudson RA; Hanson CA; Ketterling RP; Tefferi A
Leukemia; 2012 Nov; 26(11):2439-41. PubMed ID: 22705991
[No Abstract] [Full Text] [Related]
40. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Schwartzentruber J; Korshunov A; Liu XY; Jones DT; Pfaff E; Jacob K; Sturm D; Fontebasso AM; Quang DA; Tönjes M; Hovestadt V; Albrecht S; Kool M; Nantel A; Konermann C; Lindroth A; Jäger N; Rausch T; Ryzhova M; Korbel JO; Hielscher T; Hauser P; Garami M; Klekner A; Bognar L; Ebinger M; Schuhmann MU; Scheurlen W; Pekrun A; Frühwald MC; Roggendorf W; Kramm C; Dürken M; Atkinson J; Lepage P; Montpetit A; Zakrzewska M; Zakrzewski K; Liberski PP; Dong Z; Siegel P; Kulozik AE; Zapatka M; Guha A; Malkin D; Felsberg J; Reifenberger G; von Deimling A; Ichimura K; Collins VP; Witt H; Milde T; Witt O; Zhang C; Castelo-Branco P; Lichter P; Faury D; Tabori U; Plass C; Majewski J; Pfister SM; Jabado N
Nature; 2012 Jan; 482(7384):226-31. PubMed ID: 22286061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
